KdT Ventures is a new age seed stage venture firm, with a focus on the intersection of technology and science. Our thesis is that advances in compute are allowing us to solve problems never before addressable. Our goal is to help entrepreneurs turn their own ideas and visions into successful, impactful companies.
External link for KdT Ventures
Austin, US
Durham, NC, US
Chicago , IL, US
Like this song did 13 years ago, ZymoChem just dropped the BAYSE. https://lnkd.in/ezWHTNX7
Introducing BAYSE, ZymoChem's revolutionary Super Absorbent Polymer, that is bio-based and biodegradable. BAYSE is a foundational ingredient underlying everyday products across a host industries, including absorbent hygiene. Learn more about BAYSE and how we are building a #FossilFreeFuture by clicking below. https://lnkd.in/enCnExBU
new pod!
the KdT podcast is back to unpack the first biotech IPO of 2024 - CG Oncology. in The World in a Grain of Sand, we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. in this episode, Cain McClary, MD and Phil Grayeski discuss CG Oncology, and dive into: - the various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease - supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer - CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer - challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s product - bull vs bear case for the company link to the full episode in the comments.
KdT Ventures reposted this
the 2024 edition of the Decoding Bio report is live! we analyzed many of the most impactful recent papers in AI, biosecurity, cell-based medicines, immunology, and biotech software. from the jump, a core goal of Decoding Bio has been to clearly communicate why these developments matter, why you should care, and what key challenges remain. hopefully our analysis helps make sense of the dizzying pace of progress in these fields. if not, at least enjoy the brilliant design work by Bunsen. full report: https://lnkd.in/eYbB_Jch
KdT Ventures reposted this
Thanks to Stephen Zachary and Sands Capital for hosting and to Zeshan Muhammedi Justin Yang Patrick Malone, MD PhD Alec Stapp for organizing our biomanufacturing roundtable MC’d by Jassi Pannu! Institute for Progress (IFP) KdT Ventures MBX Capital Global Health Investment Corporation Cooley LLP
new pod!
KdT Ventures is back with another episode of The World in a Grain of Sand, where we break down an S1 filing from a biotech IPO and share insights on the science, business models, and financials. Ketan Yerneni and Mack Healy dig into Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. they discuss: - base editing, and its advantages over traditional (potentially error-prone) CRISPR. - Verve’s approach for predicting off-target gene editing, a key challenge for the gene editing field. - Verve’s unique licensing strategy with Beam, Acuitas, and the Broad to secure several foundational technologies. - the competitive landscape and target product profile tradeoffs of one-and-done gene editing approaches vs other therapeutic modalities. and much more. check out the full episode in the comments.
KdT Ventures reposted this
ELEGEN today announces its first partnership with GSK- $35M to start with more to come. Cell-free, clonal, scaled (1G+)DNA manufactured in 7 days or less is the only way we enable personalized genetic medicine- and I can confidently say only ELEGEN can do this. The recent Moderna Lancet publication on their Phase II personalized Melanoma Vaccine (20 unique antigens per patient)last week said it best: "Logistical complexity is intrinsic to personalized neoepitope selection and manufacture...future development must continue to optimize methods to facilitate timely manufacturing." Sure we all know that timely manufacturing is key, but get this. The paper also mentioned in the discussion that the " delayed separation <of the two trial arms> might be partly attributable to the manufacturing time of mRNA-4157". ELEGEN will save time, money, and lives. Best kind of investment. Only frustrating part is seeing so many inferior technologies get gobs of funding based on hype. Customers see the power here, and GSK will be the first of many. #personalizedmedicine #dna #mrna #mrnavaccines
We’re thrilled to announce our collaboration with GSK to provide a fast, turnkey supply of long, accurate, high-complexity ENFINIA DNA for the development of GSK's vaccines and medicines! Read the full press release: https://bit.ly/3OCwC2b #longDNA #EnfiniaDNA #biotech #mRNAvaccines #SyntheticDNA #cellfree
Terray Therapeutics powers forward, with our announcement of the NVIDIA strategic investment. KdT Ventures continues to believe that without high quality scaled data, ML/AI does not work in science. Very few have a <real> dataset as dense and scalable as Terray- though many pitch they do, substituting in silico data (trained on what?) to pull a fast one on naive investors. Proud to have continued our participation since the seed round in a company we believe will seismically change the landscape of small molecule development.
Today is a big day for Terray. We’re excited to announce a collaboration and investment from NVentures, NVIDIA’s Venture Capital arm, to realize the promise of our new molecular language for #generativeAI in small molecule drug discovery. We believe that true change for small molecule discovery and development won’t happen in a vacuum—it will happen when the right companies strategically align to push the industry forward. Read the press release here: https://lnkd.in/gQC774Rm #drugdiscovery #AI #smallmolecules #nvidia #biotech
KdT Ventures reposted this
the founding thesis of Terray Therapeutics was that the biggest bottleneck in AI-driven drug discovery is a paucity of high-quality data at scale. five years in, Terray has built an end-to-end platform that integrates automated chemical experimentation and generative AI, all purpose-built with the end (generating safe, effective, drug-like small molecules) in mind. excited to announce a collaboration and investment in Terray from NVentures, NVIDIA's venture arm. Terray and NVIDIA will collaborate on completing SOTA chemistry foundation models, some of which will be made available on NVIDIA's BioNeMo platform for AI in drug discovery. by open-sourcing some of Terray's models, the drug discovery community will see what we see: the "unreasonable effectiveness" of high-quality experimental data in solving complex problems in drug discovery. full press release: https://lnkd.in/e-GkiUCd Eli Berlin Jacob Berlin, PhD Narbe Mardirossian
On to the next leg of the journey at Debut ! Pumped to partner with L'Oréal as we move into a proven synthetic biology business model without the technical and monetary debt of past attempts. Game time!
Live from Times Square, Nasdaq celebrated Debut’s milestone in recently closing more than $40 million in additional Series B funding led by BOLD, the venture capital fund of L'Oréal. We are so excited to be leading the next industrial transformation in beauty by creating ingredients and products that only biology can access. The best is yet to come! #Debut #biotechbeauty #biotechnology #BOLD #loreal
KdT Ventures reposted this
Today at #ESGCT2023 we were excited to announce the launch of our Dyno eCap™ 1 capsid, a field-leading AAV capsid for eye gene therapies 👁🧬. This vector transduces clinically-relevant cell types across the retina and outperforms both AAV2 and external engineered capsids in NHP experiments. Learn more about this breakthrough capsid at https://lnkd.in/eAeDC-vJ and contact bd@dynotx.com about licensing opportunities.